Evolution of the Average Target: Celldex Therapeutics, Inc.

Evolution of the Target Price: Celldex Therapeutics, Inc.

Changes in Analyst Recommendations: Celldex Therapeutics, Inc.

5e5a.g2ncutOXXJv0BlXsjnj9Mmcp-KPaxUV2KHVe41eSnGA.-h2VzpHOLOm5bDeY1BHFfQ1BlNSOs2hGcDEvhDXQzhjXW_HWtPg33YRRGA~93700bfa06dcfc80d847415d09b47474
22/07 Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says MT
22/07 Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating MT
10/06 UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating MT
20/04 Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 MT
24/03 Celldex Therapeutics Shares Rise After Wolfe Research Upgrade MT
23/03 Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44 MT
26/02 Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating MT
06/11 Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study CI
21/25/21 Mizuho Initiates Celldex Therapeutics at Outperform With $48 Price Target MT
13/25/13 Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target MT
09/25/09 UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating MT
28/25/28 Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target MT
20/25/20 Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target MT
07/24/07 Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target MT
30/24/30 Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target MT
27/24/27 Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform MT
26/24/26 Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data MT
26/24/26 Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight MT
18/24/18 Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target MT
11/24/11 Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target MT
20/23/20 TD Cowen Initiates Celldex Therapeutics at Outperform Rating MT
10/23/10 Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target MT
06/23/06 HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating MT
22/23/22 Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target MT
22/23/22 Analyst recommendations: Applovin, BAE Systems, Evercore, Jefferies, Target... Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+55.04%
+28.63%
+23.54%
+7.38%
+26.52%
+48.36%
+20.43%
-0.23%
+1.87%
+2.93%
Average +21.45%
Weighted average by Cap. +21.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
38.10USD
Average target price
59.07USD
Spread / Average Target
+55.04%
High Price Target
100.00USD
Spread / Highest target
+162.47%
Low Price Target
38.00USD
Spread / Lowest Target
-0.26%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. CLDX Stock
  4. Consensus Celldex Therapeutics, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!